PLANO, Texas, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.
During NANS, attendees are invited to visit booth #127 to learn more about Integer’s latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable devices.
“Through miniaturization, Integer is creating the next generation of differentiated platform technologies to accelerate and de-risk OEMs’ path to market for novel implantable medical devices,” said Jim Stephens, President, CRM&N. “Our broad expertise in critical components, from batteries to fully integrated implantable pulse generator systems, coupled with our leadership position in active implantables uniquely positions Integer to deliver these advancements to our customers.”
NANS attendees can also learn more about Integer’s Xcellion® Gen 3 Fast Charge (FC) Lithium Ion rechargeable implantable battery technology. Xcellion Gen 3 FC delivers best in class battery runtime and full re-charges in as little as 30 minutes.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
Investor Relations: Andrew Senn This email address is being protected from spambots. You need JavaScript enabled to view it. 763.951.8312 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 214.618.4216 |
Last Trade: | US$107.87 |
Daily Change: | 0.49 0.46 |
Daily Volume: | 159,200 |
Market Cap: | US$3.780B |
July 24, 2025 July 10, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load